Results 151 to 160 of about 2,116 (170)

Tralokinumab for uncontrolled asthma

Expert Opinion on Biological Therapy, 2013
Sabina Antoniu, Ileana Antohe
exaly  

Tralokinumab ab zwölf Jahren

ästhetische dermatologie & kosmetologie, 2023
openaire   +1 more source

The Safety and Efficacy of Anti–IL-13 Treatment with Tralokinumab (CAT-354) in Moderate to Severe Asthma: A Systematic Review and Meta-Analysis

Journal of Allergy and Clinical Immunology: in Practice, 2019
Pinhua Pan, Ruoxi He, Chengping Hu
exaly  

Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing

British Journal of Clinical Pharmacology, 2015
Iwona Stelmach, Piotr Kuna, Meena Jain   +2 more
exaly  

Dupilumab- and tralokinumab-related eye disorders

Reactions Weekly, 2022
openaire   +1 more source

Tralokinumab/upadacitinib

Reactions Weekly
openaire   +1 more source

Tralokinumab‐induced injection‐site reactions

Contact Dermatitis
Axel De Greef, Marie Baeck
openaire   +2 more sources

Targeting IL‐13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years

Allergy: European Journal of Allergy and Clinical Immunology
Emma Guttman-Yassky, Petra Arlert
exaly  

Methotrexate/Tralokinumab

Reactions Weekly
openaire   +1 more source

Treatment of AD with Tralokinumab

Kareem G. Elhage, Riley K. Spencer, Joy Q. Jin, Mitchell S. Davis, Marwa Hakimi, Tina Bhutani, Wilson Liao   +6 more
openaire   +1 more source